| 2023 | Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer | NEW ENGLAND JOURNAL OF MEDICINE |
| 2018 | CD44/CD24 and aldehyde dehydrogenase 1 in estrogen receptor-positive early breast cancer treated with tamoxifen: CD24 positivity is a poor prognosticator
| ONCOTARGET |
| 2001 | CD5와 Cytokeratin 7에 음성이고 Cytokeratin 13에 양성인 흉선 편평상피세포암 1예
| TUBERCULOSIS AND RESPIRATORY DISEASES |
| 2008 | Chemoradiotherapy with or without consolidation chemotherapy using cisplatin and 5-fluorouracil in anal squamous cell carcinoma: long-term results in 31 patients
| BMC CANCER |
| 2021 | Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial | LANCET ONCOLOGY |
| 2017 | Chemotherapy-induced irreversible alopecia in early breast cancer patients | BREAST CANCER RESEARCH AND TREATMENT |
| 2023 | Clinical activity of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer: A phase IB/II study (KCSG BR18-16)
| EUROPEAN JOURNAL OF CANCER |
| 2020 | Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinib | BREAST CANCER RESEARCH AND TREATMENT |
| 2022 | Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant | CLINICAL CANCER RESEARCH |
| 2011 | Clinical significance of progesterone receptor and HER2 status in estrogen receptor-positive, operable breast cancer with adjuvant tamoxifen. | JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY |
| 2014 | cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer
| JOURNAL OF CANCER |
| 2008 | Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy. | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2017 | Comparison of standardized uptake value of 18F-FDG-PET-CT with 21-gene recurrence score in estrogen receptor-positive, HER2-negative breast cancer
| PLOS ONE |
| 2006 | Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect | GENE THERAPY |
| 2011 | Continuous separation of breast cancer cells from blood samples using multi-orifice flow fractionation (MOFF) and dielectrophoresis (DEP). | LAB ON A CHIP |
| 2023 | Copy number aberrations in circulating tumor DNA enables prognosis prediction and molecular characterization of breast cancer | JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE |
| 2020 | Destabilization of β-catenin and RAS by targeting the Wnt/β-catenin pathway as a potential treatment for triple-negative breast cancer
| EXPERIMENTAL AND MOLECULAR MEDICINE |
| 2015 | Detection of circulating tumor cell-specific markers in breast cancer patients using the quantitative RT-PCR assay | INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY |
| 2017 | Detection of Circulating Tumor Cells in Breast Cancer Patients Using Cytokeratin-19 Real-Time RT-PCR
| YONSEI MEDICAL JOURNAL |
| 2003 | Development of a Conditional Replication Competent Adenovirus, Controlled by the Human Telomerase Promoter
| CANCER RESEARCH AND TREATMENT |
| 2017 | Different patterns in the risk of newly developed fatty liver and lipid changes with tamoxifen versus aromatase inhibitors in postmenopausal women with early breast cancer: A propensity score-matched cohort study | EUROPEAN JOURNAL OF CANCER |
| 2003 | dl-VSVG-LacZ, a VSV-G epitope incorporated adenoviurs exhibit marked enhancement in gene transduction efficiency | HUMAN GENE THERAPY |
| 2015 | Do Recent Advances in Diagnostic and Therapeutic Procedures Negate the Benefit of Postmastectomy Radiotherapy in N1 Patients With a Low Risk of Locoregional Recurrence?
| MEDICINE |
| 2005 | E1A/E1B 이중변이형 종양 선택적 살상 아데노바이러스의 개선된 암세포 살상 효과 및 항종양 효과
| Journal of Bacteriology and Virology |
| 2019 | Effect of primary tumor resection on overall survival in patients with stage IV breast cancer | BREAST JOURNAL |
| 2017 | Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer | BREAST CANCER RESEARCH AND TREATMENT |
| 2020 | Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer
| CANCER DISCOVERY |
| 2020 | Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy | CLINICAL CANCER RESEARCH |
| 2023 | Efficacy of Limited Dose Modifications for Palbociclib-Related Grade 3 Neutropenia in Hormone Receptor-Positive Metastatic Breast Cancer
| CANCER RESEARCH AND TREATMENT |
| 2001 | Efficacy of Pre - and Postoperative Chemotherapy in Patients with Osteosarcoma of the Extremities
| CANCER RESEARCH AND TREATMENT |
| 2022 | Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial | JOURNAL OF CLINICAL ONCOLOGY |
| 2016 | Epithelial-to-mesenchymal transition leads to loss of EpCAM and different physical properties in circulating tumor cells from metastatic breast cancer
| ONCOTARGET |
| 2019 | Establishment of Chemosensitivity Tests in Triple-Negative and BRCA-mutated Breast Cancer Patient-Derived Xenograft Models
| PLOS ONE |
| 2018 | External validation of IBTR! 2.0 nomogram for prediction of ipsilateral breast tumor recurrence
| Radiation Oncology Journal |
| 2017 | Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results
| CANCER RESEARCH AND TREATMENT |
| 2018 | Feasibility of Charcoal Tattooing of Cytology-Proven Metastatic Axillary Lymph Node at Diagnosis and Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Breast Cancer Patients
| CANCER RESEARCH AND TREATMENT |
| 2021 | Final results of the randomized phase 2 LEO trial and bone protective effects of everolimus for premenopausal hormone receptor-positive, HER2-negative metastatic breast cancer
| INTERNATIONAL JOURNAL OF CANCER |
| 2005 | Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer | BREAST CANCER RESEARCH AND TREATMENT |
| 2021 | Genomic landscape of extraordinary responses in metastatic breast cancer
| COMMUNICATIONS BIOLOGY |
| 2021 | Genomic Profiling of Premenopausal HR+ and HER2- Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib
| JCO PRECISION ONCOLOGY |
| 2020 | Health-Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer After Endocrine Therapy
| ONCOLOGIST |
| 2023 | Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer | JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK |
| 2023 | Impacts of Subtype on Clinical Feature and Outcome of Male Breast Cancer: Multicenter Study in Korea (KCSG BR16-09)
| CANCER RESEARCH AND TREATMENT |
| 2016 | Incidence of Febrile Neutropenia in Korean Female Breast Cancer Patients Receiving Preoperative or Postoperative Doxorubicin/Cyclophosphamide Followed by Docetaxel Chemotherapy
| JOURNAL OF BREAST CANCER |
| 2003 | Increased Cytopathic Effect of Replicating Adenovirus Expressing Adenovirus Death Protein
| CANCER RESEARCH AND TREATMENT |
| 2021 | Increased resting-state cerebellar-cortical connectivity in breast cancer survivors with cognitive complaints after chemotherapy
| SCIENTIFIC REPORTS |
| 2003 | Infusional 5-Fluorouracil, Leucovorin and Docetaxel in Advanced Gastric Cancer
| CANCER RESEARCH AND TREATMENT |
| 2003 | Infusional Fluorouracil, Etoposide, and Cisplatin (FEP) in Advanced and Relapsed Gastric Cancer | AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS |
| 2023 | Integrative modeling of tumor genomes and epigenomes for enhanced cancer diagnosis by cell-free DNA
| NATURE COMMUNICATIONS |
| 2020 | Intermediate HER2 Expression Is Associated With Poor Prognosis in Estrogen Receptor-Positive Breast Cancer Patients Aged 55 Years and Older | BREAST CANCER RESEARCH AND TREATMENT |
| 2012 | Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. | LANCET |
| 2021 | Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study | EUROPEAN JOURNAL OF CANCER |
| 2020 | Local Treatment in Addition to Endocrine Therapy in Hormone Receptor-Positive and HER2-Negative Oligometastatic Breast Cancer Patients: A Retrospective Multicenter Analysis | BREAST CARE |
| 2018 | Locoregional Treatment of the Primary Tumor in Patients With De Novo Stage IV Breast Cancer: A Radiation Oncologist's Perspective | CLINICAL BREAST CANCER |
| 2022 | Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial
| ANNALS OF ONCOLOGY |
| 2023 | Machine Learning Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy for ER+HER2- Breast Cancer: Integrating Tumoral and Peritumoral MRI Radiomic Features
| DIAGNOSTICS |
| 2016 | Magnetic Resonance Imaging after Completion of Neoadjuvant Chemotherapy Can Accurately Discriminate between No Residual Carcinoma and Residual Ductal Carcinoma In Situ in Patients with Triple-Negative Breast Cancer
| PLOS ONE |
| 2021 | Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3
| ONCOLOGIST |
| 2006 | Markedly Enhanced Cytolysis by E1B-19kD-Deleted Oncolytic Adenovirus in Combination with Cisplatin | HUMAN GENE THERAPY |
| 2017 | Meeting Highlights: The Second Consensus Conference for Breast Cancer Treatment in Korea
| JOURNAL OF BREAST CANCER |
